论文部分内容阅读
目的 :检测原癌基因蛋白 C- erb B- 2和增殖细胞核抗原 (PCNA)在乳腺良恶性病变中的表达及意义。方法 :采用免疫组化法。结果 :C- erb B- 2和 PCNA在乳腺良恶性病变中表达差异显著(P<0 .0 1 )。其中导管内乳头状瘤病中二者表达高于其它良性病变而低于乳腺癌 (P<0 .0 1 )。乳腺癌中 C- erb B- 2和 PCNA表达与肿物大小和组织学分级呈正比 (P<0 .0 5)与 ER水平和 5年生存期呈反比 (P<0 .0 1 )。结论 :C- erb B- 2和 PCNA高表达者组织分化差 ,预后不良。C- erb B- 2和PCNA可作为判定潜在恶性程度的乳腺良性病变及乳腺癌预后的指标。
Objective : To detect the expression and significance of proto-oncogene proteins C-erb B-2 and proliferating cell nuclear antigen (PCNA) in benign and malignant breast lesions. Methods: Immunohistochemistry was used. RESULTS: The expression of C-erb B-2 and PCNA was significantly different between benign and malignant breast lesions (P < 0.01). In intraductal papillomatosis, the expression of both was higher than other benign lesions and lower than that of breast cancer (P < 0.01). The expression of C-erb B-2 and PCNA in breast cancer was positively correlated with tumor size and histological grade (P<0.05), and inversely correlated with ER level and 5-year survival (P<0.01). Conclusion : The high expression of C-erb B-2 and PCNA has poor tissue differentiation and poor prognosis. C-erb B-2 and PCNA can be used as indicators of the prognosis of benign breast lesions and the prognosis of breast cancer.